Skip to content
The Policy VaultThe Policy Vault

biologic immunomodulator agentsBlue Cross Blue Shield of Oklahoma

Crohn’s disease (CD)

Initial criteria

  • Patient is currently treated and stable on the requested agent OR
  • Has tried and had an inadequate response to ONE conventional agent (6-mercaptopurine, azathioprine, corticosteroids, methotrexate) after at least a 3-month duration OR
  • Conventional agent discontinued due to lack of efficacy, diminished effect, or AE OR
  • Intolerance or hypersensitivity to ONE conventional agent OR
  • FDA labeled contraindication to ALL conventional agents OR
  • Conventional agent expected to be ineffective or cause adherence barriers, worsen comorbidities, harm, or limit function OR
  • Not in the best interest of the patient based on medical necessity OR
  • Patient tried another drug in same class as conventional agent and discontinued due to inefficacy or AE OR
  • Medication history indicates use of another biologic immunomodulator FDA labeled or supported for CD